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One causes of breast cancer is mutations in tumor suppressor genes, namely BRCA1 and BRCA2. One of the 
most common types of mutations is 185delAG , 5382InsC in the BRCA1 and 6174delT  in the BRCA2 gene. 
This mutation is called the foundation mutation which the frequency were high in the Jewish Ashkenazi 
population. The aim of this study was to detect the frequency of founder mutation in hereditary breast cancer 
patients in the North Sumatran population using the PCR-RFLP method and confirmation by sequencing. The 
results showed that there was no mutation in the population of north sumatera, this may be due to a small 
number of samples or non-specific mutations occur. 
Keywords: BRCA1; BRCA2;  mutation;  breast cancer;  PCR-RFL. 
1. Introduction 
Breast cancer is one of the most common type of cancer and contributes to causing high mortality among 
women. Breast cancer is the most common cancer in women after lung cancer [1].  
------------------------------------------------------------------------ 
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About 10% of breast cancer are hereditary breast cancer and approximately 25% of breast cancer of this type are 
caused by mutations in BRCA1 and BRCA2 genes [2]. These genes has an important role in DNA repair who 
carry mutations in these genes will increase the risk of cancer at early age [3].  
Women carrying genetic mutation in BRCA1 and BRCA2 genes will increase the risk of developing breast 
cancer in their lives particulary at the age of 70 years old (45-85%) compared with general population (12,5%) 
[4].  
Although the understanding of how mutation in BRCA1 and BRCA2 genes increasing with the number of 
studies, the variation of mutation frequency in some ethnic groups still need to be investigated. 185delAG and 
5382InsC mutation in BRCA1 and 6174delT mutation in BRCA2 are the three most frequent mutations , and 
these mutations are higher in Ashkenazi Jewish [5]. These founder mutation is also found in several countries or 
ethnic including Turkey [6], Canada, Franch and several population in Europe [7].  
A number of studies on the BRCA1 and BRCA2 gene mutations in Indonesia have distinctive factors related to 
dietary factors and heredity. Study related about mutation detection on hereditary breast cancer patients in North 
Sumatera, Indonesia have not been investigated. This makes the study about mutation of BRCA1 and BRCA2 
genes in hereditary breast cancer are necessary to investigated the effect of these gene mutations on the 
prevalence of breast cancer in population in North Sumatera. 
2. Material and Methods 
Materials used in this study are blood samples from breast cancer patients, Blood DNA extraction kit (geneaid), 
Gel Red, Primer, DNA Lader, restriction enzyme, agarose, dH2O. Instrument used in this study are autoclave, 
waterbath, vortex, Biodoc analyze (Biorad), electrophoresis (Biorad), thermocycler, micro pippet, and glass 
ware.  
The method used in this study is retropspective where medical records of breast cancer patients are obtained 
from 2 tertiary hospitals in North Sumatera. With the approval of the Director of the hospital, we obtained a 
medical record of breast cancer patients from 2016 to 2017 as 29 patients.  
Each patients have to fill informed consent and we explain the objectives of the research. After we obtained the 
approval of the patients we started the experimental section by extracting DNA from peripheral blood. 
DNA Extraction and Gene amplification 
DNA was extracted from peripheral blood using manufacture’s protocols. The DNA were stored in freezer at -
20°C until analysis.  
The isolated DNA was checked by gel electrophoresis and then DNA was processes for the PCR amplification. 
The coding regions of BRCA1 and BRCA2 gene were amplified using specific primers (Table 1). 
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Table 1: Primers used for each mutation 
Primers name Primers sequence 
BRCA1  185delAG-F 5’TGA CTT ACC AGA TGG GAG AC 3’ 
BRCA1 185deAG-R 5’GAA GTT GTC ATT TTA TAA ACC TTT 3’ 
BRCA1 5382InsC-F 5’ GGG AAT CCA AAT TAC ACA GC 3’ 
BRCA1 5382InsC-R 5’ CCA AAG CGA GCA AGA GAA TCT 3’ 
BRCA2 6174delT-F 5’ TGG GAT TTT TAG CAC AGC ACG 3’ 
BRCA2 6174delT-R 5’ CTG GTC TGA ATG TTC GTT AC 3’ 
 
The program of PCR for BRCA1 185delAG were consisted of denaturation, annealing, extension and final 
extension. The program were given in table 2. 
Table 2: PCR program for BRCA1 185delAG 
PCR steps Temperature (°C) Duration  Cycle 
Initial Denaturation 95 7 min  
 
35 cycles 
Denaturation 95 30 s 
Annealing 59,4 30 s 
Extension 72 30 s 
Final extension 72 7 min 
 
The program of PCR for BRCA1 185delAG were given in table 3. 
Table 3: PCR program for BRCA1 185delAG 
PCR steps Temperature (°C) Duration  Cycle 
Initial Denaturation 95 3 min  
 
35 cycles 
Denaturation 95 30 s 
Annealing 52 30 s 
Extension 72 30 s 
Final extension 72 10 min 
 
And the PCR program for BRCA2 6174delT were given in table 4. 
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Table 4: PCR program for BRCA2 6174delT 
PCR steps Temperature (°C) Duration  Cycle 
Initial Denaturation 95 7 min  
 
35 cycles 
Denaturation 95 30 s 
Annealing 59,4 30 s 
Extension 72 30 s 
Final extension 72 7 min 
 
The PCR product then proceed with electhophoresis agarose gel 1,5% which already mixed with 3µL Gel Red. 
After the electrophoresis completed, proceed with visualization using gel documentation.  
Mutation Detection of BRCA1 and BRCA2 gene using PCR-RFLP 
To detect mutation in BRCA1 and BRCA2 genes, the PCR-RFLP method was used using specific restriction 
enzymes. The restriction enzymes used for BRCA1 185delAG, BRCA1 5382InsC and BRCA2 6174delT were 
HinfI, DdeI and Pm1I respectively. The components for the reactions consisted of 13µL ddH2O, 2µL Buffer 
Tango, restriction enzyme 1µL and PCR product were mixed into PCR tubes. Spin down for a few seconds so 
that the components are at the bottom of the tube. Incubation conducted at 37°C for 16hours the inactivation of 
the enzyme was conducted at 65°C for 20 minutes. The result of RFLP were observed wiyh electrophoresis 
using 2% agarose gel which has been added with Gel Red. The interpretation of elektrophoregram resulted for 
BRCA1 185delAG restriction product is if there are 2 DNA bands (150bp and 20bp) then the sample has wild 
type allele. If 3 DNA bands are obtained (170bp, 150bp and 20bp) then the sample has a heterozygous mutant 
allele. 
The interpretation of electrophoregram resulted for BRCA1 5382InsC  restriction product is if there are 3 DNA 
bands ( 214 bp, 36bp and 20bp) then the sample has wild type allele. If there are 2 DNA bands (36bp and 
234bp) the the samples has mutant homozygous allele and if there are 4 DNA bands (26bp, 234bp, and 214bp 
and 20bp) then the samples has heterozygous mutant allele.  
The interpretation of electrophoregram  resulted from BRCA2 6174delT restriction product is if there are 2 
DNA bands resulted (128bp and 20bp) the the samples have wild type allele, if there is 1 DNA band (148bp) the 
the samples has mutant homozygous allele and of there are 4 DNA bands (148bp, 128bp and 214bp and 20bp) 
then the sampples has mutant heterozygous allele. After the PCR-RFLP were conducted, PCR product the 
purified and send to Macrogen (Korea) for sequencing. 
3. Results 
Restriction reaction BRCA1 185delAG using HinfI Restriction Enzyme 
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The electrophoregram of restriction result of BRCA1 185delAG using HinfI was showed in Figure 1, below. 
 
Figure 1: Visualization of PCR-RFLP BRCA1 185delAG after digested by HinfI 
From figure above it is showed that wells number 4,5,6,9,10,12,13,16,22,23,24,25,26 and 27 are samples that 
digested by HinfI, LD is DNA ladder. From the result of PCR-RFLP for BRCA1 185delAG, there are 5 samples 
from 29 (17,24%) patients  which have heterozygous mutant allele (170bp, 150bp and 20bp).The sequence of 
PCR-RFLP produk of BRCA1 185delAG was showed in Figure 2. 
 
Figure 2: sequence of BRCA1 185delAG after digested with restriction enzyme HinfI 
From figure 2 it is indicate what there is a restriction site of G*ACTC by restriction enzyme, resulting 2 DNA 
bands of wild type allele. Murray and his colleagues [8] reported that the HinfI restriction enzyme would cut on 
the G*ANTC, since N= A, C, G or T. Based on PCR-RFLP result, from 29 hereditary breast cancer patients, 
there were 5 samples with heterozygous mutant alleles, thus the percentage of heterozygous mutant alleles was 
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17,24%. Based on the result it could be explained that the gene sequencing could not be represented to 
determine mutation in the form of deletion. BRCA1 185delAG mutations occur in the case of deletion of AG 
starting at the 185th nucleotide position occuring in the BRCA1 exon 2 [9]. 
Restriction reaction BRCA1 5382InsC using DdeI Restriction Enzyme 
The electrophoregram of restriction result of BRCA1 5382InsC using DdeI was showed in  
 
Figure 3: visualization of PCR-RFLP BRCA1 5382InsC digested by restriction enzyme DdeI 
From figure 3 it showed that all of the PCR-RFLP product of BRCA1 5382InsC was 1 single band of DNA 
(270bp). The similar result were also reported by Jara and his colleagues [10], which reported the 5382InsC 
mutations in healthy Chilean women with a family history of breast cancer. All samples from healthy women 
with a history of breast cancer then isolated, amplified and digested with restriction enzymes. The RFLP 
resulted a 270 bp DNA band. The sequences of PCR-RFLP BRCA1 5382InsC was showed in figure 4. 
 
Figure 4: sequence of BRCA1 5382InsC after digested with restriction enzyme DdeI 
The restriction enzyme DdeI wil cut on the CT*GAG sequence. Based on PCR-RFLP  and sequencing result, 
there is no mutation found in all samples of hereditary breast cancer. The absence of these gene mutations is 
likely due to the small number of samples or caused by non specific mutation for this population. 
Restriction reaction BRCA2 6174delT using Pm1I Restriction Enzyme 
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The electrophoregram of restriction result of BRCA2 6174delT  using Pm1I was showed in Figure 4. 
 
Figure 5: visualization of PCR-RFLP BRCA2 6174delT after digested by restriction enzyme Pm1I 
 
Figure 6: sequencing result of PCR RFLP product of BRCA2 6174delT after  digested with Pm1I 
From the figure it is known that the visualization of digested PCR product (well 1-10) resulting in 2 DNA bands 
of 20bp and 128bp (wild type allele). Result of digested PCR product from patients with hereditary breast 
cancer showed no mutation in the population. The sequences of PCR-RFLP BRCA2 6174delT was showed in 
figure 6. 
Based on figure 6, the restriction enzyme will cut on the CAC*GTG sequence, so if the allele is wild type allele, 
it will cut the into 2 parts with the size 20bp and 128bp. From the sequencing result there was no mutation  
6174delT among 29 patients with hereditary breast cancer. 
The first step in PCR-RFLP analysis is amplification of a fragment containing the variation. This is folloser by 
treatment of the amplified fragment with an appropriate restriction enzyme. Important advantages of PCR-RFLP 
technique include inexpensiveness and lack of requirement for advanced instruments. In addition, the design of 
PCR-RFLP analysis generally is easy and can be accomplished using public available programs. Disadvantages 
including the requirement for specific endonucleases and difficultis in identifying the exact variation in the 
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event that several SNP’s affect the same restriction enzyme recognition site. Another disdvantages is this 
method requires that a variation generates or abolishes a restriction enzyme recognition site [11]. 
The same result were also reported by Ghanim and his colleagues [12]. In their research, it was reported that the 
frequency of 185delAG and 5382InsC mutations was not present in patients with hereditary breast cancer in 
Iraqi population. As many as 80 breast cancer patients are withdrawn their blood samples for the analysis of 
mutation frequency using multiplex PCR. It can be explained that the possibility of other types of mutations has 
a higher frequency than the mutations observed in the study. 
3 specific mutations responsible for the BRCA1 gene mutations (185delAG and 5382InsC) and BRCA2 
(6174delT) accounted for 85% of the Jewish Ashkenazi ethnicity. The risk for breast and ovarian cancer is 
significantly increased in women who carry one or more of these 3 mutations [13].  
4, Conclusion 
Based on PCR-RFLP method and sequencing of BRCA1 185delAG mutation, BRCA1 5382 insC and BRCA2 
6174delT on hereditary breast cancer patient in North Sumatera. The absence of these three mutations in breast 
cancer patients in this study may be influenced by ethnic, mixed ethnicity through marriage and geographic 
location. 
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